CFTR and cystic fibrosis: The basic defect caused by F508del mutation, the most frequent among CF patients, can be highly corrected with a combination of small molecules called “correctors”, which act by improving the stability of CFTR protein and its trafficking to the plasma membrane [34,35,36].